Takeda Pharmaceutical Ltd ADR TAK

$20.24 -0.12 (-0.59%)

Valuation

Market cap
65,239,204,000
Revenue TTM
$29,737,750,000
Net income TTM
$-1,005,770,000
PE ratio
11.86
Forward PE
12.80
Profit margin
-3.38%
Debt to equity
0.65

Trading

Volume
2,099,200
Avg volume
2,500,526
Day's range
$20.17 – $20.39
Shares out
3,204,283,000
Stochastic %K
92%
Beta
-0.07
Analysts
Strong Sell
Price target
$22.63

Price

Company profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Re...

Show more

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
81 3 3278 2111
Website
https://www.takeda.com
Address
1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan

Latest news

Stocktwits

Warebuffe Oct 23, 11:47 AM
$TAK $VKTX today 🔥Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
0 replies
Warebuffe Oct 23, 11:44 AM
$TAK Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
0 replies
Warebuffe Oct 23, 11:41 AM
$TAK These potentially practice-changing data from G-HOPE-001 not only support the path toward our first regulatory filing and continued global development of arcotatug tavatecan but also mark meaningful progress in translating promising science into new treatment options for patients
0 replies
Investor6 Oct 23, 9:15 AM
28 Japanese stocks are listed in the major U.S. markets. The ranking by EV/EBITDA is, starting with the most undervalued 8 stocks: $TOYO still suffers by $50 million June/2026 dilution MWC 2026 IPO $SONY IX underfollowed stock $LFS $TAK HMC Honda TM Disclaimer: I hold shares of MWC.
0 replies
Quantumup Oct 21, 12:54 PM
Piper Sandler reiterated $ABVX Overweight-$175 and said -- Obefazimod's Differentiated Profile Reinforced by UEGW Data $TAK $PTGX - JNJ SYRE CRVS ABBV PALI RHHBY MRK TEVA Here's what else Piper Sandler had to say in its note: https://x.com/Quantumup1/status/2112889927583109267?s=20
1 replies
lebranjames Oct 20, 8:33 PM
$TAK 52 week high
1 replies
Arabroad Oct 16, 6:53 PM
$TAK primed for a bump and run
0 replies
Quantumup Oct 16, 11:11 AM
H.C. Wainwright reiterated $HALO Buy-$130 and said -- Switching Takeda's primary immunodeficiency patients from GAMMAGARD LIQUID or CUVITRU to TAK-881 could add Halozyme royalties. $TAK $RHHBY JNJ ARGX LLY ORKA BMY PFE VRTX GSK ABBV GMAB CHGCY ABOS SKYE TEVA H.C. Wainwright added — On October 14, Takeda (TAK; not rated) presented detailed Phase 2/3 IgGNITE results for its investigational 20% subcutaneous immunoglobulin (SCIG) with Halozyme's recombinant human hyaluronidase (ENHANZE) in primary immunodeficiency (PID). Median single-site infusions took 75.8 vs. 132 minutes with HYQVIA, a 42.6% reduction; two-site infusions took 58.3 vs. 86 minutes, a 32.2% reduction. The same IgG dose required half the volume, with dosing every three to four weeks. We think these gains could retain HYQVIA patients and attract patients from Takeda's own non-ENHANZE GAMMAGARD LIQUID and CUVITRU, expanding Halozyme's royalty base even with flat Takeda immunoglobulin sales.
0 replies